Aerie Pharmaceuticals, an Irvine, California-headquartered pharmaceutical company focused on glaucoma and other eye diseases, has entered into a research, development, and license agreement with DSM, a global science-based company active in health, nutrition, and materials.

The research collaboration agreement includes an option to license DSM’s bioerodible polymer implant technology for evaluating its application to the delivery of certain Aerie compounds, initially focused on retinal diseases. DSM’s technology uses polyesteramide polymers to produce an injectable, thin fiber.

Source: DSM